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Cancer mortality does not differ 
by antiarrhythmic drug use: A 
population-based cohort of Finnish 
men
Kalle J. Kaapu1, Lauri Rantaniemi1, Kirsi Talala2, Kimmo Taari3, Teuvo L. J. Tammela1,4, 
Anssi Auvinen5 & Teemu J. Murtola1,4
In-vitro studies have suggested that the antiarrhythmic drug digoxin might restrain the growth of 
cancer cells by inhibiting Na+/K+-ATPase. We evaluated the association between cancer mortality 
and digoxin, sotalol and general antiarrhythmic drug use in a retrospective cohort study. The study 
population consists of 78,615 men originally identified for the Finnish Randomized Study of Screening 
for Prostate Cancer. Information on antiarrhythmic drug purchases was collected from the national 
prescription database. We used the Cox regression method to analyze separately overall cancer 
mortality and mortality from the most common types of cancer. During the median follow-up of 17.0 
years after the baseline 28,936 (36.8%) men died, of these 8,889 due to cancer. 9,023 men (11.5%) 
had used antiarrhythmic drugs. Overall cancer mortality was elevated among antiarrhythmic drug 
users compared to non-users (HR 1.43, 95% CI 1.34–1.53). Similar results were observed separately for 
digoxin and for sotalol. However, the risk associations disappeared in long-term use and were modified 
by background co-morbidities. All in all, cancer mortality was elevated among antiarrhythmic drug 
users. This association is probably non-causal as it was related to short-term use and disappeared in 
long-term use. Our results do not support the anticancer effects of digoxin or any other antiarrhythmic 
drug.
Various preclinical studies have suggested that the antiarrhythmic drug digoxin may have antineoplastic effects1–3. 
Digoxin may be able to inhibit growth of lung4–6, prostate7,8 and pancreatic9 tumor cell lines and suppress cancer 
progression. The anticancer effects have been suggested to be due to inhibition of the plasma membrane Na+/
K+-ATPase which increases intracellular concentration of Ca2+, eventually causing apoptosis7,10. Another pro-
posed mechanism is inhibition of HIF-1alpha, an important regulator of cell growth8,11.
Digoxin use might be associated with a decreased risk of prostate cancer12, especially among patients under 
regular PSA-surveillance13,14, but is not associated with prostate cancer-specific survival15–17. In a British cohort 
study there was no association between digoxin use and cancer-specific survival from prostate, breast, respira-
tory or gastrointestinal cancer18. Further, digoxin use was not associated with survival among ovarian cancer 
patients19.
Digoxin has estrogenic effects20 and has been associated with an increased risk of breast21 and uterine can-
cer but digoxin users may have a better prognosis and a decreased risk of metastases22–24. Digoxin use has also 
been linked to a higher risk of colorectal cancer25 but no difference in cancer-specific survival after diagnosis of 
colorectal cancer was found in a population-based cohort study26.
Studies concerning other antiarrhythmic drugs and cancer survival are sparse. The beta-blocker sotalol is both 
a K+-channel blocker and used clinically as an antiarrhythmic drug. Adrenergic activation is essential for cancer 
and therefore the use of beta-blockers might be beneficial27. We have previously shown in a population-based 
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case-control study that sotalol is associated with a lowered prostate cancer risk28 but does not associate with sur-
vival17. Beta-blockers as a group have been linked with prolonged cancer survival29.
We estimated the association between use of digoxin, sotalol or other antiarrhythmic drugs and overall 
cancer mortality and separately lung, colorectal, pancreatic, liver, bladder, renal and CNS cancer mortality in a 
population-based cohort of Finnish men.
Results
Population characteristics. A total of 78,615 men with data from the SII prescription database were 
included in the study. Of these 9,023 (11.5%) had used at least one antiarrhythmic drug during the follow-up; 
6,329 (8.1%) had used digoxin and 2,304 (2.9%) had used sotalol. The median age at baseline was 59 years among 
the never-users of antiarrhythmic drugs and 63 years among men with any antiarrhythmic drug use during the 
follow-up.
During the median follow-up of 17.0 years after baseline, 28,936 (36.8%) men died. There were 8,889 cancer 
deaths altogether, and the most frequent individual cancers were lung cancer (2,384 deaths), colorectal cancer 
(861 deaths) and pancreatic cancer (782 deaths) (Table 1).
In general, the use of other drugs (NSAIDs, aspirin, statins, antidiabetic drugs, antihypertensive drugs, 
alpha-blockers and 5-alpha-reductase inhibitors) was more common and the Charlson comorbidity index (CCI) 
was higher among antiarrhythmic drug users compared to non-users (Table 1).
Antiarrhythmic drug use and overall cancer mortality. Antiarrhythmic drug use in general 
was associated with increased cancer mortality in both age-adjusted and multivariable-adjusted analyses 
(multivariable-adjusted HR 1.43, 95% CI 1.34–1.53,). A similar risk increase was observed for men with digoxin 
use (HR 1.59, 95% CI 1.47–1.72) and sotalol use (HR 1.16, 95% CI 1.03–1.31) (Table 2). The risk increase attenu-
ated with increasing amount, duration and intensity of drug use but there was no risk decrease even in long-term 
use (Table 3). Furthermore, the risk elevation tended to decrease also in lagged analysis estimating long-term 
effects of antiarrhythmic drug use (Table 2).
Antiarrhythmic drug use Digoxin use Sotalol use
Never Ever P-value Never Ever P-value Never Ever P-value
Characteristics of Participants
Number of participants 69,592 9,023 72,286 6,329 76,311 2,304
Median Age (IQR) 59 (55–63) 63 (59–67) 0.00 59 (55–63) 63 (59–67) 0.00 59 (55–63) 63 (59–67) 0.00
Median BMI (IQR) 26.3 (24.2–28.7) 27.2 (24.8–30.3) 0.00 26.3 (24.2–28.7) 27.4 (25.1–30.9) 0.00 26.3 (24.2–29.0) 27.2 (25.0–30.2) 0.00
Baseline cancer diagnosis 
(any) 2,822 (4.1%) 457 (5.1%) 0.00 2,956 (4.1%) 323 (5.1%) 0.00 3,165 (4.1%) 114 (4.9%) 0.06
Charlson comorbidity index 0.00 0.00 0.00
0 50,305 (72.3%) 4,703 (52.1%) 52,097 (72.1%) 2,911 (46.0%) 53,653 (70.3%) 1,355 (58.8%)
1 3,192 (4.6%) 614 (6.8%) 3,322 (4.6%) 484 (7.6%) 3,683 (4.8%) 123 (5.3%)
2 or greater 16,095 (23.1%) 3,706 (41.1%) 16,867 (23.3%) 2,934 (46.4%) 18,975 (24.9%) 826 (35.9%)
Cancer death
Overall cancer death 7,873 (11.3%) 1,016 (11.3%) 8,143 (11.3%) 746 (11.8%) 8,622 (11.3%) 267 (11.6%)
Lung cancer death 2,090 (3.0%) 294 (3.3%) 2,152 (3.0%) 232 (3.7%) 2,320 (3.0%) 64 (2.8%)
Colorectal cancer death 770 (1.1%) 91 (1.0%) 792 (1.1%) 69 (1.1%) 846 (1.1%) 15 (0.7%)
Pancreatic cancer death 714 (1.0%) 68 (0.8%) 734 (1.0%) 48 (0.8%) 762 (1.0%) 20 (0.9%)
Gastric cancer death 316 (0.5%) 27 (0.3%) 321 (0.4%) 22 (0.3%) 336 (0.4%) 7 (0.3%)
Hepatic cancer 425 (0.6%) 48 (0.5%) 436 (0.6%) 37 (0.6%) 454 (0.6%) 19 (0.8%)
Renal cancer 251 (0.4%) 35 (0.4%) 259 (0.4%) 27 (0.4%) 277 (0.4%) 9 (0.4%)
Non-Hodgkin lymphoma 256 (0.4%) 46 (0.5%) 267 (0.4%) 35 (0.6%) 295 (0.4%) 7 (0.3%)
Bladder cancer 190 (0.3%) 29 (0.3%) 198 (0.3%) 21 (0.3%) 215 (0.3%) 4 (0.2%)
Central nervous system 
cancer 191 (0.3%) 17 (0.2%) 198 (0.3%) 10 (0.2%) 203 (0.3%) 5 (0.2%)
Prevalence of medication use
NSAIDs 54,837 (78.8%) 7,436 (82.5%) 0.00 57,145 (79.1%) 5,128 (81.0%) 0.00 60,311 (79.0%) 1,962 (85.2%) 0.00
Aspirin 10,732 (15.4%) 1,647 (18.3%) 0.00 11,287 (15.6%) 1092 (17.3%) 0.00 11,894 (15.6%) 485 (21.1%) 0.00
Statins 28,014 (40.3%) 4,840 (53.6%) 0.00 29,540 (40.9%) 3,314 (52.4%) 0.00 31,489 (41.3%) 1,374 (59.6%) 0.00
Antidiabetic drugs 13,321 (19.1%) 2,572 (28.5%) 0.00 13,871 (19.2%) 2,022 (31.9%) 0.00 15,274 (20.0%) 619 (26.8%) 0.00
Antihypertensives 44,472 (63.9%) 8,459 (93.7%) 0.00 46,878 (64.9%) 6,053 (95.6%) 0.00 50,731 (66.5%) 2,200 (95.5%) 0.00
Alpha-blockers 18,442 (26.5%) 2,901 (32.2%) 0.00 19,399 (26.8%) 1,944 (30.7%) 0.00 20,554 (26.9%) 789 (34.2%) 0.00
Table 1. Population characteristics in the Finnish Randomized Study of Screening for Prostate Cancer.
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Antiarrhythmic drug use and individual cancers. Both usage of antiarrhythmic drugs in general and 
usage of digoxin were associated with increased lung cancer mortality (HR 1.72, 95% CI 1.52–1.95 and HR 2.10, 
95% CI 1.82–2.41, respectively). This association was not observed for sotalol use (HR 1.10, 95% CI 0.85–1.41) 
(Table 2). There were similar trends by amount, duration and intensity as with overall cancer mortality (Table 3).
The results for colorectal cancer mortality were rather similar to those for lung cancer mortality; 
Antiarrhythmic drug use in general and digoxin use both elevated risk of death (HR 1.38, 95% CI 1.11–1.73 and 
HR 1.59, 95% CI 1.24–2.05). Usage of sotalol was not associated with the risk for colorectal cancer death (HR 
0.70, 95% CI 0.42–1.17) (Table 2).
Pancreatic cancer differed from other cancer types since antiarrhythmic drug use had no influence on pan-
creatic cancer mortality (HR 1.02, 95% CI 0.79–1.31). Identical findings were observed for digoxin use (HR 1.06, 
95% CI 0.79–1.43) and for sotalol use (HR 0.99, 95% CI 0.63–1.54).
Furthermore, antiarrhythmic drug use and digoxin use were associated with elevated risk of death due to 
non-Hodgkin lymphoma and bladder cancer (Table S1).
Subgroup analysis. The overall cancer mortality of antiarrhythmic drug users was increased in all sub-
groups that we analyzed (Fig. 1). The risk estimates for overall cancer death were most increased among non-users 
of antihypertensive drugs (p for interaction 0.01). There was a similar risk difference between users and non-users 
of antihypertensive drugs among digoxin users (p for interaction 0.002). Furthermore, there was an interaction by 
antidiabetic drug use, the risk being higher among men who were not using antidiabetic drugs (p for interaction 
0.01) (Fig. 1).
We used the CCI to stratify the study population by comorbidities. Antiarrhythmic drug use associated 
with increased cancer mortality among the men with least comorbidities (Charlson index 0: HR 1.37, 95% CI 
1.19–1.56). A similar result was observed among men with intermediate comorbidities (Charlson index 1: HR 
1.22, 95% CI 0.87–1.71) but the CIs are wider since there were less men in this cohort. There was no association 
between cancer mortality and antiarrhythmic drug use among men with the most comorbidities (Charlson index 
2 or greater: 0.98, 95% CI 0.91–1.06). There was a statistically significant effect modification by CCI (p for inter-
action < 0.001).
Sensitivity analysis. To evaluate confounding by indication we estimated the risk association between the 
indications for antiarrhythmic drug and digoxin use (cardiac insufficiency and arrhythmias) and cancer mor-
tality. 4,199 men had recorded diagnosis of cardiac insufficiency (ICD-10 codes I50) in the HILMO database, 
while 1,507 men had a diagnosis of arrhythmia (I47 and I49). The increase in overall cancer mortality risk that 
we observed for cardiac insufficiency (HR 1.19, 95% CI 1.08–1.31) was similar to the risk for antiarrhythmic drug 
use in general that we observed in our main analysis. However, having a recorded diagnosis of arrhythmia was 
associated with a lowered risk of cancer death (HR 0.76, 95% CI 0.64–0.90). There was no association between 
antiarrhythmic drug use and cancer mortality in competing risk analyses. The HR for overall antiarrhythmic drug 
Antiarrhythmic 
drug use
Overall cancer deatha
Lung cancer 
death
Colorectal cancer 
death
Pancreatic cancer 
death
Age-adjusted 
model
Multivarible-
adjusted modelb
Multivarible-
adjusted modelc
Multivarible-
adjusted modelc
Multivarible-
adjusted modelc
HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI)
No use Ref Ref Ref Ref Ref
Any use 1.40 (1.31–1.50) 1.43 (1.34–1.53) 1.72 (1.52–1.95) 1.38 (1.11–1.73) 1.02 (0.79–1.31)
Lag 3 v 1.24 (1.15–1.34) 1.26 (1.17–1.36) 1.39 (1.20–1.61) 1.36 (1.07–1.74) 0.98 (0.74–1.30)
Lag 5 v 1.21 (1.12–1.31) 1.23 (1.13–1.33) 1.29 (1.10–1.51) 1.42 (1.10–1.82) 0.99 (0.74–1.33)
Digoxin use
No use Ref Ref Ref Ref Ref
Any use 1.60 (1.48–1.73) 1.59 (1.47–1.72) 2.10 (1.82–2.41) 1.59 (1.24–2.05) 1.06 (0.79–1.43)
Lag 3 v 1.35 (1.23–1.47) 1.33 (1.21–1.45) 1.59 (1.34–1.88) 1.53 (1.15–2.02) 1.00 (0.72–1.40)
Lag 5 v 1.30 (1.18–1.44) 1.28 (1.16–1.41) 1.49 (1.23–1.79) 1.59 (1.19–2.14) 0.97 (0.67–1.39)
Sotalol use
No use Ref Ref Ref Ref Ref
Any use 1.11 (0.98–1.25) 1.16 (1.03–1.31) 1.10 (0.85–1.41) 0.70 (0.42–1.17) 0.99 (0.63–1.54)
Lag 3 v 1.11 (0.98–1.26) 1.16 (1.02–1.32) 1.07 (0.82–1.39) 0.83 (0.51–1.37) 0.98 (0.61–1.57)
Lag 5 v 1.08 (0.95–1.24) 1.14 (0.99–1.30) 0.98 (0.74–1.31) 0.89 (0.54–1.47) 1.06 (0.66–1.69)
Table 2. Antiarrhythmic drug use and cancer mortality in Finnish Randomized Study of Screening for Prostate 
Cancer. aIncluding lung, prostate, colorectal, pancreatic, gastric, liver, renal, non-Hodgkin lymphoma, bladder 
and central nervous system cancer. bFrom Cox regression model adjusted for age, screening trial arm and use 
of cholesterol-lowering, antidiabetic and antihypertensive drugs, aspirin and other NSAIDs, 5alpha-reductase 
inhibitors, alpha-blockers and cancer diagnose at baseline. cFrom Cox regression model adjusted for age and use 
of cholesterol-lowering, antidiabetic and antihypertensive drugs, aspirin and other NSAIDs, 5alpha-reductase 
inhibitors, alpha-blockers and cancer diagnose at baseline.
www.nature.com/scientificreports/
4SCienTiFiC REPORTs |  (2018) 8:10308  | DOI:10.1038/s41598-018-28541-4
use was 1.04 (95% CI 0.97–1.12). For digoxin and sotalol users the HRs were 1.01 (95% CI 0.93–1.10) and 1.03 
(95% CI 0.91–1.17), respectively.
Both overall antiarrhythmic drug use (HR 1.13, 95% CI 1.05–1.21) and digoxin use (HR 1.13, 95% CI 1.05–
1.23) were associated with increased cancer mortality in a sensitivity analysis adjusted by the CCI. However, the 
risk estimates were lower compared to the main analyses. In this analysis, sotalol use had no effect on cancer 
mortality (HR 0.98, 95% CI 0.86–1.10). In addition, the CCI was independently associated with an increased risk 
of cancer death; HR 1.51, 95% CI 1.50–1.52 per increase of one point.
All-cause mortality among antiarrhythmic drug users was increased compared to non-users (HR 2.14, 95% 
CI 2.07–2.21). Digoxin users had an even greater risk of death (HR 2.52, 95% CI 2.43–2.61), whereas sotalol 
users had a minor, but nevertheless statistically significant, increase in mortality (HR 1.35, 95% CI 1.27–1.44). 
Excluding prevalent cancers at baseline from analysis did not modify results (Table S2).
Compared to the users of other antiarrhythmic drugs, digoxin users had an increased risk of cancer death (HR 
3.06, 95% CI 2.64–3.54). Sotalol use was not associated with cancer mortality (HR 1.12, 95% CI 0.99–1.32 in a 
similar sensitivity analysis.
Discussion
The usage of antiarrhythmic drugs was associated with elevated overall cancer mortality and with increased lung 
cancer mortality in this retrospective cohort study. Digoxin users had a more prominent increase in risk estimates 
for cancer death, compared to overall antiarrhythmic drug users. The individual cancer types with increased mor-
tality by digoxin use were lung cancer, colorectal cancer, bladder cancer and non-Hodgkin lymphoma. Usage of 
sotalol and cancer mortality had no association in the age-adjusted analysis but in the multivariable analysis users 
had a statistically significant increase in the risk of cancer-specific death.
Digoxin’s mechanism of action differs from other classic antiarrhythmic drugs. Vaughan Williams classifi-
cation is used to categorize antiarrhythmic agents by mechanism of action. Class I is divided to subclasses Ia, Ib 
and Ic, all of which are Na+-channel blockers. Class II includes beta-blockers (excluding sotalol) and Class III 
K+-channel blockers. Finally, Ca2+-channel blockers form class IV and agents with unknown or other mecha-
nisms form class V. Digoxin belongs to the Class V and is a Na+/K+-ATPase inhibitor. This increases intracel-
lular Na+-concentration leading to decreased activity of Na+/Ca2+-exchanger. Eventually, this cascade results in 
increased concentration of calcium-ions, which might induce apoptosis7,10.
All antiarrhythmic drugs Digoxin Sotalol
Overall cancer 
mortality
Lung cancer 
mortality
Pancreatic 
cancer mortality
Overall cancer 
mortality
Lung cancer 
mortality
Pancreatic 
cancer mortality
Overall cancer 
mortality
Lung cancer 
mortality
Pancreatic 
cancer 
mortality
HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a HR (95% CI)a
Cumulative quantity of medication useb
DDD tertiles
1st tertile 1.85 (1.67–2.05) 2.22 (1.84–2.67) 1.30 (0.87–1.92) 1.97 (1.76–2.21) 2.47 (2.00–3.04) 1.31 (0.83–2.07) 1.18 (0.97–1.44) 1.29 (0.88–1.88) 0.84 (0.38–1.88)
2nd tertile 1.39 (1.25–1.55) 1.88 (1.56–2.28) 0.95 (0.62–1.45) 1.59 (1.39–1.81) 2.03 (1.59–2.58) 1.14 (0.69–1.88) 1.15 (0.93–1.43) 1.17 (0.77–1.76) 1.07 (0.51–2.25)
3rd tertile 1.10 (0.97–1.25) 1.07 (0.83–1.38) 0.84 (0.54–1.32) 1.22 (1.06–1.41) 1.77 (1.39–2.27) 0.78 (0.45–1.35) 1.14 (0.92–1.42) 0.79 (0.47–1.34) 1.07 (0.51–2.26)
Duration of medication usec
Year tertiles
1st tertile 1.72 (1.56–1.89) 2.14 (1.80–2.55) 1.14 (0.78–1.67) 1.84 (1.66–2.05) 2.46 (2.04–2.96) 1.35 (0.90–2.02) 1.32 (1.09–1.60) 1.53 (1.07–2.18) 0.72 (0.30–1.74)
2nd tertile 1.36 (1.22–1.51) 1.72 (1.41–2.09) 0.77 (0.49–1.23) 1.61 (1.41–1.84) 2.18 (1.72–2.76) 0.86 (0.48–1.52) 1.00 (0.81–1.22) 0.88 (0.57–1.35) 0.74 (0.33–1.65)
3rd tertile 1.13 (0.98–1.30) 1.06 (0.79–1.43) 1.17 (0.75–1.82) 1.17 (0.99–1.38) 1.37 (0.99–1.88) 0.86 (0.47–1.56) 1.21 (0.95–1.53) 0.84 (0.48–1.49) 1.75 (0.90–3.38)
Intensity of medication use (DDDs/year)d
Intensity tertiles
1st tertile 1.91 (1.72–2.11) 2.26 (1.87–2.74) 1.25 (0.83–1.89) 2.13 (1.91–2.38) 2.71 (2.22–3.30) 1.30 (0.82–2.05) 1.19 (0.97–1.46) 1.25 (0.85–1.86) 1.18 (0.59–2.36)
2nd tertile 1.42 (1.26–1.59) 1.75 (1.41–2.16) 1.08 (0.71–1.66) 1.49 (1.28–1.74) 1.93 (1.46–2.56) 0.91 (0.49–1.71) 1.22 (0.99–1.50) 1.04 (0.67–1.61) 1.10 (0.52–2.32)
3rd tertile 1.10 (0.98–1.24) 1.30 (1.05–1.61) 0.80 (0.52–1.23) 1.20 (1.06–1.37) 1.68 (1.33–2.11) 0.97 (0.61–1.53) 1.08 (0.87–1.34) 0.99 (0.63–1.56) 0.71 (0.29–1.71)
Table 3. Cancer mortality by amount, duration and intensity of antiarrhythmic drug use in the the Finnish 
Randomized Study of Screening for Prostate Cancer. aFrom Cox regression model adjusted for age, screening 
trial arm (only for overall cancer mortality) and use of cholesterol-lowering, antidiabetic and antihypertensive 
drugs, aspirin and other NSAIDs, and 5alpha-reductase inhibitors and alpha-blockers. bTertile cut-points for 
cumulative amount of medication use: All antiarrhythmic drugs combined 1st tertile: 1–280 DDD, 2nd tertile: 
281–1,400 DDD, 3rd tertile: more than 1,400 DDD; Digoxin 1st tertile: 1–200 DDD, 2nd tertile: 201–960 DDD, 
3rd tertile: more than 960 DDD; Sotalol 1st tertile: 1–200 DDD, 2nd tertile: 201–1,230 DDD, 3rd tertile: more than 
1,230 DDD. cTertile cut-points for cumulative duration of medication use: All antiarrhythmic drugs combined 
1st tertile: 1–2 years, 2nd tertile: 3–7 years, 3rd tertile: longer than 7 years; Digoxin 1st tertile: 1–2 years, 2nd tertile: 
3–6 years, 3rd tertile: longer than 6 years; Sotalol 1st tertile: 1 year, 2nd tertile: 2–5 years, 3rd tertile: longer than 5 
years. dTertile cut-points for intensity of medication use: All antiarrhythmic drugs combined 1st tertile: 1–116 
DDDs/year, 2nd tertile: 117–228 DDDs/year, 3rd tertile: more than 229 DDDs/year; Digoxin 1st tertile: 1–100 
DDDs/year, 2nd tertile: 101–170 DDDs/year, 3rd tertile: more than 170 DDDs/year; Sotalol 1st tertile: 1–120 
DDDs/year, 2nd tertile: 121–285 DDDs/year, 3rd tertile: more than 285 DDDs/year.
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Divergences between users and non-users (confounding by indication) provide a likely explanation for the 
observed increase in cancer mortality. When we analyzed the association between cardiac insufficiency (the indi-
cation) and cancer mortality, a comparable risk elevation was observed. Furthermore, the risk increase tended 
to disappear with increasing amount, duration and intensity of antiarrhythmic drug use, suggesting that the 
increased mortality is unlikely to be caused by antiarrhythmic drug use but rather by residual confounding by 
unmeasured background differences between antiarrhythmic drug uses and non-users. If the drugs did indeed 
increase the risk, an opposite trend would be presumed.
Digoxin users are likely more fragile than non-users, which may cause non-causal risk differences in epide-
miological studies. This explanation was supported by subgroup analyses stratified by the CCI; among men with 
a low co-morbidity burden, digoxin use was associated with an increased risk of cancer death. However, among 
men with a high co-morbidity burden, the risk difference disappeared. This confirms that the risk association is 
modified by background co-morbidities. Further, the CCI was an independent risk factor for cancer death. In the 
competing risk analyses antiarrhythmic drug use was not associated with cancer mortality, further supporting the 
notion that use of digoxin or other antiarrhythmic drugs does not affect cancer mortality when non-cancer deaths 
are taken into account. When compared to users of other antiarrhythmic drugs, digoxin users had an increased 
cancer mortality. Therefore, the co-morbidity burden may differ even between users of different antiarrhythmic 
drugs.
Our main results are slightly inconsistent with previously published ones. There are no studies concerning 
overall cancer mortality and few studies about individual cancer types. In vitro studies have suggested that digoxin 
might have a suppressive effect on lung neoplasms via multiple mechanisms; it has been shown that digoxin hin-
ders tumor progression by inhibiting the activation of an important oncogene Src4. Moreover, digoxin decreases 
the expression of VEGF and NDRG1 through inhibition of HIF-1alpha synthesis5 and induces autophagy through 
the regulation of mTOR and ERK1/2 signaling pathways in non-small cell lung cancer cells6. A Swedish study 
observed that digoxin users had a diminished risk of lung neoplasms (HR 0.55, 95% CI 0.39–0.79) compared to 
users of organic nitrates30. Nonetheless, these chemopreventive features of digoxin did not translate into dimin-
ished lung cancer mortality in our large population-based study.
One population-based cohort study regarding colorectal cancer survival has previously been published26. 
The study included 10,357 patients with a colorectal cancer diagnosis and during the median follow-up of 4.8 
years 2,724 colorectal cancer–specific deaths occurred. Before model adjustments digoxin use was associated 
with elevated colorectal cancer–specific mortality (HR 1.25, 95% CI 1.07–1.46), but the association disappeared 
after adjustment for confounders (HR 1.10, 95% CI 0.91–1.34). In our study, digoxin users had slightly elevated 
colorectal cancer mortality in the multivariable adjusted analysis. This inconsistency is probably due to differences 
Figure 1. Overall cancer mortality by overall antiarrhythmic drug use and by digoxin use versus non-use 
stratified by patient characteristics in the the Finnish Randomized Study of Screening for Prostate Cancer.
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in adjustment-models. Karasneh et al.26 were able to adjust the analysis for received radiotherapy, chemotherapy 
or surgery within 6 months and for comorbidities more comprehensively compared to us.
Interestingly, pancreatic cancer differed from other cancer types. There was no association between pancreatic 
cancer mortality and digoxin use, whereas there was a statistically significant risk increase for other major cancer 
types. It has been observed that there is an elevated level of HIF-1alpha expression in pancreatic cancer31 and a 
previous study observed that intraperitoneal digoxin injections significantly reduced pancreatic tumor volume 
compared to placebo-injections9. Furthermore, the same study noticed that digoxin injections decreased the 
expression of stem cell factor (SCF), a cytokine commonly involved in tumor progression. However, these path-
ways should be relevant also for other cancer types besides pancreatic cancer. Thus, the differing risk association 
between digoxin use and pancreatic cancer could be due to other causes.
In contrast to other cancer types, there was no association between sotalol use and death due to lung and 
colorectal cancer. Sotalol is both a beta-blocker and K+-channel blocker and it is possible that these properties 
may overcome the otherwise increased cancer mortality among antiarrhythmic drug users in these cancer types. 
Another possibility is that sotalol users had a different distribution of co-morbidities and therefore confound-
ing by indication could have less of an effect. Furthermore, the number of sotalol users was lower compared to 
digoxin users, resulting in wider confidence intervals and less robust results.
Our study had several strengths. First, we had a large population-based cohort that comprehensively repre-
sents the Finnish male population. Additionally, detailed information on antiarrhythmic drug purchases was 
available, allowing us to calculate the individual amounts and durations of drug use. Consequently, we were able 
to perform time-dependent regression analyses in order to control for the immortal time bias. We were able to 
adjust for comorbidities and drugs regularly used along with antiarrhythmic drugs since the information was 
available from the national registries.
On the other hand, a few limitations should be discussed. There was no information on exact indications of 
antiarrhythmic drug use even though we were able to separately evaluate the most common indications. We also 
lacked data on lifestyle habits such as diet, alcohol consumption, smoking and physical activity, all of which may 
be risk factors for cancer death. Furthermore, there was no information on tumor grade, metastases or given 
treatment. Since we were not able to adjust analyses by these factors, confounding is possible. Smoking is a risk 
factor for both cardiac diseases and cancer death thus it could be a confounding factor increasing observed cancer 
mortality among antiarrhythmic drug users. We did not have information on frequency of health care contacts. 
This might have been greater among antiarrhythmic drug users and therefore leading to earlier detection of tum-
ors, which might result in lower observed cancer mortality.
Our information on medication use is based on reimbursed drug purchases. We do not know for sure whether 
or not patients have actually used the drugs they have bought. Finally, the study population was originally 
recruited for a prostate cancer screening trial. The cohort included principally Caucasian men so there is no cer-
tainty whether the results can be generalized to women or other ethnic groups.
Conclusion
We observed that antiarrhythmic drug use has neither general cancer protective effects nor a beneficial impact 
on any particular cancer type. In contrast, cancer mortality was increased among antiarrhythmic drug users 
compared to non-users, but the risk increase was likely non-causal as it was related to short-term use only and 
disappeared in long-term use. Our results do not support the hypothesis of digoxin’s anticancer effects or those of 
any other antiarrhythmic drug.
Material and Methods
Study cohort. We used the population of the Finnish Randomized Study of Screening for Prostate Cancer 
(FinRSPC), which is the largest component of the European Randomized Study of Screening for Prostate Cancer 
(ERSPC). The detailed trial protocol has been described previously32. In short, 80,458 men were recruited to the 
study during the years 1996–1999. Men were randomized to either the screening arm (31,866 men, prostate-spe-
cific antigen test at 4-year intervals) or control arm (48,278 men, no intervention, followed through national 
cancer registry). The follow-up continued until the end of 2015. Prevalent prostate cancer cases at baseline were 
excluded; no exclusions for other cancers were made.
The official causes of death in 1996–2015 were obtained from the death certificate registry of Statistics Finland. 
FinRSPC cause-of-death committee has previously found Statistics Finland to be a dependable source of data 
(kappa 0.95)33. The data included primary, immediate and contributory causes of death recorded as ICD-10 
codes. For this study we collected information on deaths with lung (C34), colorectal (C18), pancreatic (C25), 
gastric (C16), liver (C22), renal (C64), non-Hodgkin lymphoma (C81), bladder (C67) or central nervous system 
cancer (C71 and C72) recorded as the primary cause of death. Prostate cancer deaths were included in overall 
cancer mortality. We have previously performed a separate analysis for the risk of prostate cancer death17.
Information on diagnoses recorded during in- and outpatient hospital contacts during 1996–2012 were 
obtained from the Care Register for Health Care (HILMO) of the National Institute for Health and Welfare. The 
data was used to calculate the CCI for the study participants. Additionally, we sought information on indications 
for antiarrhythmic drug use: heart failure (ICD-10 code I50) and cardiac arrhythmias (I47 and I49).
The study was approved by the Ethics Committee of the Pirkanmaa Health Care District, Finland (tracking 
number R10167) and the Committee confirmed that all research was performed in accordance with relevant 
guidelines. Informed consent was obtained from all participants in the screening arm of the study.
Information on medication use. We collected data on antiarrhythmic drug purchases during 1995–2015 
from the reimbursement database of the Social Insurance Institution of Finland (SII). SII is a governmental 
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agency that provides reimbursements for physician-prescribed drug purchases to all Finnish citizens as part of a 
national health insurance. All reimbursed purchases are registered in the database that records the date, number 
of packages acquired, and number and dosage of the tablets for every purchase. This information allowed us to 
calculate the amount of the medication purchases for each drug on a yearly basis.
Antiarrhythmic drug purchases were identified with drug-specific ATC–codes. Drugs in clinical use during 
the study period were amiodarone, digoxin, disopyramide, etilefrine, flecainide, quinidine, mexiletine, procaina-
mide, propafenone and sotalol. Additionally, we obtained information on use of statins, antidiabetic medication 
(oral glucose-lowering drugs and insulins), antihypertensive medication (beta-blockers, ACE-inhibitors/ATII 
receptor blockers, calcium-channel blockers, diuretics and other types of drugs, such as methyldopa and cloni-
dine), aspirin and other NSAIDs, 5-alpha-reductase inhibitors and alpha-blockers.
Statistical analysis. The baseline characteristics were compared between ever-users and never-users of anti-
arrhythmic drugs using the Chi-square test for categorical variables and the Mann-Whitney U test for continuous 
variables. The association between antiarrhythmic drug use and cancer mortality was estimated using the Cox 
proportional hazards regression. We estimated hazard ratios (HR) and their 95% confidence intervals (CIs) for 
cancer death overall and for deaths due to specific types of cancer by antiarrhythmic drug use. We analyzed 
mortality by overall antiarrhythmic drug use and separately by digoxin and sotalol use. The follow-up time was 
calculated from FinRSPC randomization to the date of death, emigration or the common closing date (December 
31th 2015), whichever occurred first.
Antiarrhythmic drug use was analyzed as a time-dependent variable to minimize immortal time bias. 
Therefore, we updated the medication use status prospectively for every year of follow-up by annual medication 
purchases. If there was a recorded purchase at any point during a year, the man was regarded as a user. If medica-
tion purchases were stopped during the follow-up, the participant remained in the user category to minimize bias 
due to selective discontinuation of medication use in the terminal phase of cancer. Men without any purchases 
during the follow-up and all users before the first purchase were classified as non-users, which was used as the ref-
erence group in the main analyses. Age-adjusted and multivariable analyses (further adjustment for baseline can-
cer diagnosis and use of other drug groups: drugs used in management of benign prostatic hyperplasia, diabetes, 
hypercholesterolemia or hypertension, and aspirin and other NSAIDs) were conducted. Besides antiarrhythmic 
drugs, use of other drugs was included in the analyses as a time-independent variable.
We standardized amounts of antiarrhythmic drugs use by dividing the cumulative annual milligram amount 
of each drug with the standard Defined Daily Dose (DDD) published on the WHO website34. By adding together 
years with antiarrhythmic drug purchases, we were able to estimate cumulative duration of drug use. Intensity 
of drug use (DDDs/year) was calculated by dividing the cumulative annual amount with duration of medication 
use. We stratified men into tertiles by the variables mentioned above to estimate whether the amount or duration 
of drug use affects mortality.
Effect modification by age, baseline cancer, use of other drug groups and socioeconomic factors was evaluated 
in subgroup analyses stratified according to these variables. The statistical significance of each effect modifier was 
evaluated by adding an interaction term between antiarrhythmic drug use and the background variable into the 
multivariable-adjusted Cox regression model.
We evaluated the long-term effects of antiarrhythmic drug use in lag-time analyses, in which the 
time-dependent status of antiarrhythmic drug use was lagged forward 3–5 years in follow-up time. These analyses 
were carried out to minimize confounding by indication, as especially digoxin is commonly used in management 
of potentially lethal congestive heart failure. In addition, we performed competing risk regression analyses with 
non-cancer deaths as the competing risk. These analyses were conducted according to the method reported by 
Fine and Gray35.
The statistical tests were two-sided. P-values of 0.05 or less were considered statistically significant. IBM SPSS 
Statistics 23 (Chicago, IL, USA) software was used for data analyses.
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